(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9670136B2 · kind B2 · utility
6Cited by
19References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 1, 2016 |
| Grant date | Jun 6, 2017 |
| Priority date | — |
| Expiry date | Sep 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.